[A19-82] Fremanezumab (migraine) - Addendum to Commission A19-44

Last updated 07.11.2019

Project no.:
A19-82

Commission:
Commission awarded on 24.09.2019 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Head and nerves

Indication:

Migraine prophylaxis in adult patients with at least 4 migraine days per month

Result of dossier assessment:

Based on subsequently submitted analyses, there is now an indication of non-quantifiable added benefit

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2019-11-07 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form